xpeer logo

© 2026 XPEER MEDED, S.L. · Av. del Portal de l'Àngel, 38, 4º 5ª, 08002 Barcelona, Spain · All rights reserved

Privacy Policy - Terms of Use - Help

Register now for free!

Over 100,000 doctors have already joined Xpeer — register now to find out why, and get instant access to this course and many more.

I already have an account
Course Preview

Realizing precision haematology in CLL: why we need biomarkers

4.7

Accredited (Credits: 3)
Free
3h 1min
Audio: German +3
Subtitles: German +3

Synopsis

The increasing prevalence of chronic lymphocytic leukemia (CLL) prompts an increased need for predictive and prognostic biomarkers. However, the vast and evolving array of biomarkers poses challenges for some physicians in integrating them into CLL management. This course, led by global key opinion leaders, provides practical expertise and includes the latest data from major medical conferences. After reviewing current CLL treatments and exploring future trends, participants will delve into predictive and prognostic biomarkers, essential in treatment decision-making. Additionally, participants will explore the value and relevance of measurable residual disease (MRD) assessment and its methodological considerations. The course also includes the analysis of clinical cases for practical application of the concepts discussed. Elevate your practice with updated knowledge, ensuring improved patient outcomes in CLL management! This activity is supported by an Independent Medical Education grant from MSD.

Accreditation

This course is accredited with 3 ECMEC credits valid in 26 countries. To claim your credits take the evaluation (satisfaction survey and evaluation questionnaire). You have 3 attempts for the evaluation. You need to pass the evaluation with a sufficient score to validate the course. Your diploma is issued instantaneously and sent to your email.

See more information on the accreditation at: Accreditation

Duration

3h 1min

Target audience

Hematology, Medical oncology, Allergy, Immunology, Internal medicine, Medical genetics, Other

Authors

Prof. Dr. Paolo Ghia

Paolo Ghia, MD, PhD, is a full professor in medical oncology at the Università Vita-Salute San Raffaele, and deputy chairman of the Division of Experimental Oncology, at IRCCS Ospedale San Raffaele, Milan (Italy), where he is also head of the Laboratory of B-Cell Neoplasia and director of the strategic research program on CLL.

Conflicts of interests statement:

Paolo Ghia declares the receipt of honoraria or consultation fees from AstraZeneca, AbbVie, MSD, BeiGene, BMS, Janssen, Lilly/Loxo, Sanofi and Roche, and receiving research support from AstraZeneca, AbbVie, BMS and Janssen.

Testimonials

“Excellent platform to stay up to date and keep learning throughout your professional career. I recommend it to all my colleagues.”

Omar I. onTrustpilot

Spain

“Xpeer is a magnificent platform for healthcare professionals, where you can gain knowledge from a scientific and highly up-to-date perspective across various medical specialties.”

Wil A. onTrustpilot

Netherlands

“I've taken several courses on Xpeer and they've been very useful. The format is very dynamic, allowing you to watch the videos in your free time since they're no longer than 15 minutes. The topics are very current.”

Francisco P. onTrustpilot

Spain

Read more reviews onTrustpilot

FAQs

What you will learn

Before you begin

  • Pre-course assessment: please complete to help us personalise your learning experience

Trailer

  • Trailer

The current treatment landscape in CLL – What the future holds

  • Presentation by Prof. Dr. Ghia
  • The pillars of CLL treatment
  • First-generation BTK inhibitors
  • Second-generation BTK inhibitors
  • Third-generation BTK inhibitors
  • Treatment modalities: how can we improve?
  • Insights into the future and conclusions

Prognostic and predictive CLL biomarkers

  • Presentation by Prof. Dr. Stilgenbauer
  • Staging systems and prognostication
  • Biomarker: Prognostic or predictive?
  • Early stage: progression biomarkers
  • Advanced stage: biomarkers of response
  • Targeted agents selection
  • Clinical impact with BTK inhibitors
  • Clinical impact with BCL-2 antagonists
  • Guidelines recommendations on CLL treatment and prognostic factors
  • Clinical decision-making parameters beyond prognostic markers
  • Concluding remarks on CLL prognostic biomarkers

Disease monitoring, measurable residual disease (MRD)

  • Presentation by Dr. Rawstron
  • Introduction to MRD
  • Relevance in CLL outcomes
  • Available assays
  • Flow cytometry
  • Molecular assays
  • What should be the treatment target?
  • Peripheral blood or bone marrow?
  • Comparison of different methods and conclusions
  • MRD in clinical practice: potential applications
  • MRD in clinical practice: recommendations and conclusions

Clinical cases discussion and concluding remarks

  • Clinical case #1 (part 1)
  • Clinical case #1 (part 2)
  • Clinical case #2 (part 1)
  • Clinical case #2 (part 2)
  • Course conclusion

Accreditation - Evaluation

  • Satisfaction survey
  • Multiple-choice test

Register now for free!

Over 100,000 doctors have already joined Xpeer — register now to find out why, and get instant access to this course and many more.

I already have an account